Frequently Asked Questions
What does the study involve?
The study will last for about three years – 8 weeks to see if you or a loved one qualify, followed by receiving the investigational drug for 3 years, then 4 weeks of follow-up.
The investigational medication is a tablet, to be taken once a day. The tablet will contain either a lower dose of the investigational medication, a higher dose of the investigational medication, or a placebo, depending on which group you are assigned to. A placebo tablet is one that contains no active ingredients.
The participant will be assigned at random to one of the three study groups. Neither the participant nor the study doctor will know which group the participant has been assigned to. There is a 2 in 3 chance that the participant will receive the investigational medication. If it is necessary to find out which group the participant has been assigned to, the study doctor can do so quickly.
The participant will need a study partner. This person needs to be someone who the participant is in regular contact with, who will go with the participant to study appointments, and who can answer questions about the participant to help the study team detect any changes in the participant’s mental functioning.
If you or a loved one joins the study, you or a loved one and a study partner will be asked to attend around 29 clinic appointments. During these appointments, we will assess the participant’s health, thinking, and memory with some standard medical tests and questionnaires. We will also ask the participant or study partner about any side effects the participant may be experiencing. These appointments will be every 3 weeks for the first few visits and then every 7 weeks until the end of the study.
What else should you know about the study?
If you or a loved one are already receiving treatment for Alzheimer’s disease, it may be possible to continue taking the treatment. The study team will let you know.
There is no guarantee that the investigational drug will improve the participant’s memory or symptoms.
The participant’s safety is our first priority. Throughout the study, the participant’s health will be carefully monitored at all appointments.
The investigational drug will be stopped if the participant or the study doctor have any concerns, or if the participant or study partner changes his/her mind about being in the study.
The investigational drug and all study-related care will be provided free of charge.
The participant may be compensated up to $150 per clinic visit for time and travel.